Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Renal Insufficiency, Chronic | 59 | 2024 | 2306 | 4.110 |
Why?
|
Kidney Failure, Chronic | 33 | 2023 | 2505 | 3.090 |
Why?
|
Renal Dialysis | 18 | 2023 | 1790 | 2.540 |
Why?
|
Diabetic Nephropathies | 16 | 2024 | 975 | 2.440 |
Why?
|
Kidney Transplantation | 19 | 2023 | 4278 | 2.160 |
Why?
|
Calcinosis | 9 | 2013 | 1480 | 1.640 |
Why?
|
Glomerular Filtration Rate | 34 | 2024 | 2232 | 1.630 |
Why?
|
Coronary Artery Disease | 12 | 2022 | 6575 | 1.110 |
Why?
|
Erectile Dysfunction | 4 | 2021 | 437 | 1.030 |
Why?
|
Nephrology | 4 | 2023 | 270 | 0.900 |
Why?
|
Kidney Diseases | 11 | 2023 | 2101 | 0.760 |
Why?
|
Disease Progression | 22 | 2023 | 13642 | 0.650 |
Why?
|
Kidney | 17 | 2024 | 7073 | 0.620 |
Why?
|
Renal Replacement Therapy | 2 | 2021 | 282 | 0.620 |
Why?
|
Albuminuria | 10 | 2023 | 659 | 0.590 |
Why?
|
Cardiovascular Diseases | 22 | 2024 | 15652 | 0.580 |
Why?
|
Diabetes Mellitus, Type 2 | 14 | 2024 | 12246 | 0.580 |
Why?
|
Interleukin-6 | 5 | 2022 | 3226 | 0.560 |
Why?
|
Diabetes Mellitus | 8 | 2022 | 5888 | 0.540 |
Why?
|
Diabetic Retinopathy | 2 | 2023 | 1300 | 0.540 |
Why?
|
Lipoprotein(a) | 3 | 2007 | 489 | 0.480 |
Why?
|
Arteriovenous Shunt, Surgical | 3 | 2017 | 291 | 0.460 |
Why?
|
Fibroblast Growth Factors | 4 | 2016 | 871 | 0.440 |
Why?
|
Coronary Vessels | 4 | 2014 | 3115 | 0.400 |
Why?
|
C-Reactive Protein | 4 | 2021 | 3853 | 0.390 |
Why?
|
Health Literacy | 3 | 2014 | 466 | 0.390 |
Why?
|
Heart Valves | 1 | 2013 | 284 | 0.380 |
Why?
|
Catheters, Indwelling | 2 | 2012 | 436 | 0.370 |
Why?
|
Diabetes Mellitus, Type 1 | 6 | 2023 | 3446 | 0.360 |
Why?
|
Polytetrafluoroethylene | 1 | 2012 | 242 | 0.360 |
Why?
|
Humans | 133 | 2024 | 766812 | 0.350 |
Why?
|
Middle Aged | 70 | 2024 | 223267 | 0.330 |
Why?
|
Graft Survival | 5 | 2023 | 3904 | 0.330 |
Why?
|
Hypertriglyceridemia | 2 | 2003 | 292 | 0.310 |
Why?
|
Allopurinol | 2 | 2020 | 203 | 0.300 |
Why?
|
Male | 80 | 2024 | 364154 | 0.300 |
Why?
|
United States Government Agencies | 1 | 2008 | 26 | 0.300 |
Why?
|
Adult | 60 | 2024 | 223305 | 0.300 |
Why?
|
Cohort Studies | 31 | 2022 | 41706 | 0.300 |
Why?
|
Kidney Function Tests | 8 | 2024 | 685 | 0.290 |
Why?
|
Prospective Studies | 32 | 2022 | 54872 | 0.290 |
Why?
|
Tunica Intima | 1 | 2009 | 455 | 0.280 |
Why?
|
Renal Insufficiency | 3 | 2023 | 811 | 0.280 |
Why?
|
Minority Health | 1 | 2008 | 79 | 0.280 |
Why?
|
Blood Pressure | 5 | 2021 | 8533 | 0.280 |
Why?
|
Aged | 54 | 2024 | 171344 | 0.260 |
Why?
|
Female | 75 | 2024 | 396532 | 0.260 |
Why?
|
Cholesterol, HDL | 3 | 2014 | 1814 | 0.260 |
Why?
|
Glaucoma | 1 | 2015 | 1194 | 0.250 |
Why?
|
Uric Acid | 3 | 2022 | 809 | 0.250 |
Why?
|
Heart Valve Diseases | 1 | 2013 | 1029 | 0.250 |
Why?
|
Aorta | 2 | 2011 | 2043 | 0.250 |
Why?
|
Carotid Stenosis | 1 | 2012 | 858 | 0.240 |
Why?
|
Acute Kidney Injury | 3 | 2024 | 1946 | 0.240 |
Why?
|
Carotid Arteries | 1 | 2009 | 932 | 0.240 |
Why?
|
Renin-Angiotensin System | 5 | 2020 | 736 | 0.240 |
Why?
|
Cystatin C | 3 | 2023 | 272 | 0.240 |
Why?
|
Health Priorities | 1 | 2008 | 380 | 0.240 |
Why?
|
Atherosclerosis | 4 | 2024 | 3421 | 0.230 |
Why?
|
Coronary Disease | 3 | 2014 | 5915 | 0.230 |
Why?
|
Heart Failure | 10 | 2024 | 11879 | 0.220 |
Why?
|
Proteinuria | 3 | 2019 | 613 | 0.220 |
Why?
|
Hyperglycemia | 2 | 2022 | 1389 | 0.220 |
Why?
|
Risk Factors | 32 | 2024 | 74889 | 0.220 |
Why?
|
Creatinine | 7 | 2024 | 1917 | 0.220 |
Why?
|
United States | 26 | 2024 | 72945 | 0.210 |
Why?
|
Proteomics | 4 | 2024 | 3915 | 0.210 |
Why?
|
Efficiency, Organizational | 1 | 2008 | 695 | 0.210 |
Why?
|
Lipocalins | 2 | 2014 | 160 | 0.210 |
Why?
|
Sleep Apnea Syndromes | 1 | 2011 | 982 | 0.210 |
Why?
|
Aortic Diseases | 1 | 2009 | 741 | 0.210 |
Why?
|
Myocardial Infarction | 7 | 2021 | 11514 | 0.210 |
Why?
|
Acute-Phase Proteins | 2 | 2014 | 251 | 0.200 |
Why?
|
Osteopontin | 1 | 2024 | 305 | 0.200 |
Why?
|
Health Policy | 2 | 2021 | 2697 | 0.200 |
Why?
|
Diet, Sodium-Restricted | 1 | 2024 | 291 | 0.200 |
Why?
|
Resistin | 1 | 2022 | 174 | 0.190 |
Why?
|
Organ Transplantation | 2 | 2003 | 1172 | 0.190 |
Why?
|
Prevalence | 9 | 2020 | 15835 | 0.190 |
Why?
|
Coronary Stenosis | 1 | 2007 | 804 | 0.180 |
Why?
|
Peripheral Arterial Disease | 3 | 2021 | 1304 | 0.180 |
Why?
|
Inflammation | 4 | 2016 | 10863 | 0.180 |
Why?
|
Xanthine Oxidase | 1 | 2020 | 69 | 0.170 |
Why?
|
Adipokines | 1 | 2022 | 308 | 0.170 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2001 | 213 | 0.170 |
Why?
|
Aspartate Aminotransferases | 1 | 2021 | 416 | 0.170 |
Why?
|
Cultural Diversity | 1 | 2023 | 370 | 0.170 |
Why?
|
Insulin Resistance | 1 | 2013 | 3989 | 0.160 |
Why?
|
Policy | 1 | 2023 | 512 | 0.160 |
Why?
|
Alleles | 2 | 2023 | 6896 | 0.160 |
Why?
|
Kidney Tubules | 2 | 2024 | 454 | 0.160 |
Why?
|
Regression Analysis | 4 | 2013 | 6329 | 0.160 |
Why?
|
Glomerulonephritis, Membranoproliferative | 1 | 1999 | 41 | 0.160 |
Why?
|
Troponin T | 2 | 2014 | 786 | 0.160 |
Why?
|
Hypoglycemic Agents | 5 | 2024 | 3108 | 0.160 |
Why?
|
Sodium | 3 | 2022 | 1594 | 0.160 |
Why?
|
Spin Labels | 1 | 2020 | 334 | 0.150 |
Why?
|
Alanine Transaminase | 1 | 2021 | 608 | 0.150 |
Why?
|
Cryoglobulinemia | 1 | 1999 | 84 | 0.150 |
Why?
|
Hyperlipidemias | 1 | 2003 | 771 | 0.150 |
Why?
|
Metformin | 2 | 2024 | 907 | 0.150 |
Why?
|
Cardiomyopathies | 2 | 2024 | 2058 | 0.150 |
Why?
|
Financing, Government | 1 | 2021 | 473 | 0.140 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2010 | 1897 | 0.140 |
Why?
|
Serine Endopeptidases | 1 | 2022 | 1027 | 0.140 |
Why?
|
Research Personnel | 1 | 2021 | 589 | 0.140 |
Why?
|
Research Support as Topic | 1 | 2021 | 697 | 0.140 |
Why?
|
Risk Adjustment | 1 | 2020 | 597 | 0.140 |
Why?
|
Thyroid Diseases | 1 | 2000 | 385 | 0.130 |
Why?
|
Adiponectin | 1 | 2022 | 1121 | 0.130 |
Why?
|
Proportional Hazards Models | 9 | 2021 | 12536 | 0.130 |
Why?
|
Obesity, Abdominal | 2 | 2016 | 372 | 0.130 |
Why?
|
Incidence | 8 | 2024 | 21527 | 0.130 |
Why?
|
Hematoma | 1 | 2020 | 766 | 0.130 |
Why?
|
Hypertrophy, Left Ventricular | 4 | 2015 | 856 | 0.120 |
Why?
|
Body Mass Index | 5 | 2016 | 13050 | 0.120 |
Why?
|
Obesity | 4 | 2021 | 13090 | 0.120 |
Why?
|
Single-Cell Analysis | 2 | 2024 | 2535 | 0.120 |
Why?
|
Health Status Disparities | 3 | 2021 | 1880 | 0.120 |
Why?
|
Cause of Death | 4 | 2021 | 3717 | 0.120 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2010 | 4056 | 0.120 |
Why?
|
Uromodulin | 1 | 2014 | 49 | 0.120 |
Why?
|
Exercise | 1 | 2011 | 5945 | 0.120 |
Why?
|
Hypertension | 3 | 2024 | 8616 | 0.120 |
Why?
|
Cross-Sectional Studies | 10 | 2020 | 26309 | 0.120 |
Why?
|
N-Acetylgalactosaminyltransferases | 1 | 2014 | 63 | 0.120 |
Why?
|
Tissue Donors | 2 | 2023 | 2392 | 0.120 |
Why?
|
Hepacivirus | 1 | 2021 | 1343 | 0.120 |
Why?
|
Patient Education as Topic | 1 | 2024 | 2334 | 0.110 |
Why?
|
Leptin | 1 | 2022 | 1596 | 0.110 |
Why?
|
Bicarbonates | 1 | 2015 | 293 | 0.110 |
Why?
|
Drug Therapy, Combination | 1 | 2024 | 6306 | 0.110 |
Why?
|
Natriuretic Peptide, Brain | 3 | 2024 | 1750 | 0.110 |
Why?
|
Adiposity | 2 | 2014 | 1892 | 0.110 |
Why?
|
Hepatitis C, Chronic | 1 | 2021 | 1033 | 0.110 |
Why?
|
Fibrinogen | 2 | 2014 | 893 | 0.100 |
Why?
|
Patient Preference | 1 | 2020 | 946 | 0.100 |
Why?
|
Markov Chains | 2 | 2017 | 974 | 0.100 |
Why?
|
Catheterization, Central Venous | 1 | 2017 | 538 | 0.100 |
Why?
|
Lymphoma, B-Cell | 1 | 1999 | 945 | 0.100 |
Why?
|
Chromatin | 1 | 2024 | 2980 | 0.100 |
Why?
|
Hospitalization | 5 | 2020 | 10816 | 0.100 |
Why?
|
Young Adult | 15 | 2020 | 59939 | 0.100 |
Why?
|
Health Care Costs | 2 | 2017 | 3240 | 0.090 |
Why?
|
Proto-Oncogene Proteins | 2 | 2014 | 4523 | 0.090 |
Why?
|
Apolipoproteins | 1 | 2013 | 328 | 0.090 |
Why?
|
Potassium | 1 | 2015 | 1314 | 0.090 |
Why?
|
Risk Assessment | 9 | 2024 | 24299 | 0.090 |
Why?
|
Intra-Abdominal Fat | 1 | 2016 | 624 | 0.090 |
Why?
|
Osteoprotegerin | 1 | 2011 | 179 | 0.090 |
Why?
|
Quality of Health Care | 2 | 2018 | 4306 | 0.090 |
Why?
|
Multivariate Analysis | 6 | 2016 | 12064 | 0.090 |
Why?
|
Waist-Hip Ratio | 1 | 2012 | 521 | 0.090 |
Why?
|
Immunosuppressive Agents | 3 | 2010 | 4215 | 0.090 |
Why?
|
Pulsatile Flow | 1 | 2011 | 318 | 0.090 |
Why?
|
Polymorphism, Single Nucleotide | 6 | 2017 | 16044 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 7 | 2017 | 20710 | 0.090 |
Why?
|
Piperazines | 1 | 2001 | 2547 | 0.090 |
Why?
|
Cadherins | 1 | 2014 | 903 | 0.080 |
Why?
|
Peptide Fragments | 3 | 2024 | 5143 | 0.080 |
Why?
|
Postoperative Complications | 3 | 2008 | 15831 | 0.080 |
Why?
|
Inflammation Mediators | 2 | 2016 | 1889 | 0.080 |
Why?
|
Polycystic Kidney Diseases | 1 | 2010 | 133 | 0.080 |
Why?
|
Enzyme Inhibitors | 1 | 2020 | 3723 | 0.080 |
Why?
|
Ultrasonography, Doppler, Color | 1 | 2010 | 234 | 0.080 |
Why?
|
Intraocular Pressure | 1 | 2015 | 1304 | 0.080 |
Why?
|
Pulse | 1 | 2009 | 217 | 0.080 |
Why?
|
Survival Analysis | 3 | 2018 | 10101 | 0.080 |
Why?
|
Quality-Adjusted Life Years | 2 | 2017 | 1740 | 0.080 |
Why?
|
Cataract | 1 | 2015 | 837 | 0.080 |
Why?
|
Acculturation | 1 | 2010 | 179 | 0.080 |
Why?
|
Lipoproteins, HDL | 1 | 2013 | 678 | 0.080 |
Why?
|
Smoking | 3 | 2016 | 9077 | 0.080 |
Why?
|
Histocompatibility Testing | 2 | 2008 | 726 | 0.080 |
Why?
|
Membrane Proteins | 2 | 2022 | 7869 | 0.080 |
Why?
|
Chromosome Mapping | 1 | 2017 | 4618 | 0.080 |
Why?
|
Consensus | 3 | 2022 | 3208 | 0.080 |
Why?
|
Health Expenditures | 1 | 2021 | 2389 | 0.080 |
Why?
|
Graft Occlusion, Vascular | 1 | 2012 | 538 | 0.080 |
Why?
|
Healthcare Disparities | 2 | 2021 | 3411 | 0.070 |
Why?
|
Ankle Brachial Index | 2 | 2021 | 163 | 0.070 |
Why?
|
Genetic Loci | 1 | 2017 | 2631 | 0.070 |
Why?
|
Time Factors | 8 | 2018 | 40149 | 0.070 |
Why?
|
Sympathetic Nervous System | 1 | 2010 | 520 | 0.070 |
Why?
|
DNA Methylation | 1 | 2021 | 4427 | 0.070 |
Why?
|
Comorbidity | 4 | 2017 | 10580 | 0.070 |
Why?
|
Stroke | 3 | 2021 | 9744 | 0.070 |
Why?
|
Gene Expression Profiling | 1 | 2023 | 9528 | 0.070 |
Why?
|
Hypolipidemic Agents | 2 | 2003 | 609 | 0.070 |
Why?
|
Morbidity | 1 | 2012 | 1754 | 0.070 |
Why?
|
Fatty Liver | 1 | 2013 | 810 | 0.070 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2017 | 1456 | 0.070 |
Why?
|
Lipids | 2 | 2008 | 3322 | 0.070 |
Why?
|
Statistics as Topic | 1 | 2013 | 2350 | 0.070 |
Why?
|
Quality of Life | 3 | 2021 | 13476 | 0.070 |
Why?
|
Tacrolimus | 1 | 2010 | 753 | 0.070 |
Why?
|
Postmenopause | 1 | 2016 | 2517 | 0.070 |
Why?
|
Follow-Up Studies | 6 | 2014 | 39312 | 0.070 |
Why?
|
Vasodilation | 1 | 2010 | 968 | 0.070 |
Why?
|
Drug Utilization | 1 | 2012 | 1188 | 0.070 |
Why?
|
Odds Ratio | 4 | 2021 | 9661 | 0.070 |
Why?
|
Health Promotion | 1 | 2018 | 2209 | 0.070 |
Why?
|
HLA-A Antigens | 1 | 2007 | 223 | 0.070 |
Why?
|
Community-Institutional Relations | 1 | 2008 | 209 | 0.070 |
Why?
|
Women's Health | 1 | 2016 | 2081 | 0.070 |
Why?
|
Hemodynamics | 2 | 2020 | 4188 | 0.060 |
Why?
|
Monitoring, Physiologic | 1 | 2013 | 1794 | 0.060 |
Why?
|
Biomedical Research | 1 | 2021 | 3459 | 0.060 |
Why?
|
Insulin | 1 | 2020 | 6608 | 0.060 |
Why?
|
Pain | 1 | 2020 | 5098 | 0.060 |
Why?
|
Treatment Failure | 2 | 2020 | 2659 | 0.060 |
Why?
|
HLA-B Antigens | 1 | 2007 | 330 | 0.060 |
Why?
|
Triglycerides | 2 | 2014 | 2441 | 0.060 |
Why?
|
Prognosis | 6 | 2016 | 29959 | 0.060 |
Why?
|
HLA-DR Antigens | 1 | 2007 | 609 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 3 | 2016 | 18076 | 0.060 |
Why?
|
Computational Biology | 1 | 2017 | 3564 | 0.060 |
Why?
|
Predictive Value of Tests | 4 | 2014 | 15425 | 0.060 |
Why?
|
Tenascin | 1 | 2024 | 61 | 0.060 |
Why?
|
Genotype | 5 | 2022 | 13036 | 0.060 |
Why?
|
Mycophenolic Acid | 1 | 2006 | 349 | 0.060 |
Why?
|
Dyslipidemias | 1 | 2012 | 872 | 0.060 |
Why?
|
Fasting | 1 | 2010 | 1609 | 0.060 |
Why?
|
Sex Factors | 4 | 2021 | 10619 | 0.060 |
Why?
|
Genome-Wide Association Study | 7 | 2017 | 12808 | 0.060 |
Why?
|
Holistic Health | 1 | 2024 | 47 | 0.060 |
Why?
|
Calcium | 2 | 2014 | 5783 | 0.060 |
Why?
|
Sleep Deprivation | 1 | 2010 | 848 | 0.050 |
Why?
|
Magnetic Resonance Imaging, Cine | 1 | 2010 | 1089 | 0.050 |
Why?
|
HLA Antigens | 1 | 2008 | 1339 | 0.050 |
Why?
|
Cost-Benefit Analysis | 2 | 2017 | 5536 | 0.050 |
Why?
|
Role | 1 | 2003 | 176 | 0.050 |
Why?
|
Transplantation, Homologous | 2 | 2008 | 4860 | 0.050 |
Why?
|
Double-Blind Method | 3 | 2023 | 12430 | 0.050 |
Why?
|
Case-Control Studies | 4 | 2023 | 22248 | 0.050 |
Why?
|
Angiopoietins | 1 | 2022 | 86 | 0.050 |
Why?
|
Cathepsin D | 1 | 2022 | 59 | 0.050 |
Why?
|
Amino Acids | 1 | 2008 | 1711 | 0.050 |
Why?
|
Angiopoietin-1 | 1 | 2022 | 132 | 0.050 |
Why?
|
Mortality | 3 | 2021 | 2908 | 0.050 |
Why?
|
Guideline Adherence | 1 | 2012 | 2233 | 0.050 |
Why?
|
Energy Metabolism | 1 | 2013 | 2903 | 0.050 |
Why?
|
Echocardiography | 2 | 2015 | 5038 | 0.050 |
Why?
|
Educational Status | 1 | 2010 | 2510 | 0.050 |
Why?
|
Receptor, TIE-2 | 1 | 2022 | 183 | 0.050 |
Why?
|
Myocardium | 1 | 2015 | 4765 | 0.050 |
Why?
|
Vitamin K 1 | 1 | 2022 | 47 | 0.050 |
Why?
|
Logistic Models | 4 | 2021 | 13276 | 0.050 |
Why?
|
Primary Health Care | 1 | 2018 | 4735 | 0.050 |
Why?
|
Iohexol | 1 | 2022 | 205 | 0.050 |
Why?
|
Kidney Tubules, Proximal | 1 | 2024 | 386 | 0.050 |
Why?
|
Treatment Refusal | 1 | 2005 | 433 | 0.050 |
Why?
|
Decision Support Techniques | 1 | 2012 | 2007 | 0.050 |
Why?
|
Hemodialysis, Home | 1 | 2021 | 21 | 0.050 |
Why?
|
Angiopoietin-2 | 1 | 2022 | 186 | 0.050 |
Why?
|
Radial Artery | 1 | 2003 | 187 | 0.050 |
Why?
|
Longitudinal Studies | 4 | 2021 | 14762 | 0.050 |
Why?
|
Coronary Angiography | 2 | 2018 | 4525 | 0.050 |
Why?
|
Reoperation | 1 | 2012 | 4325 | 0.050 |
Why?
|
Hypertension, Renal | 1 | 2001 | 135 | 0.050 |
Why?
|
Survival Rate | 2 | 2013 | 12826 | 0.050 |
Why?
|
Aged, 80 and over | 7 | 2024 | 59548 | 0.050 |
Why?
|
Health Education | 1 | 2008 | 1060 | 0.050 |
Why?
|
Age Factors | 3 | 2017 | 18397 | 0.050 |
Why?
|
Naphthyridines | 1 | 2022 | 184 | 0.050 |
Why?
|
Intermittent Claudication | 1 | 2003 | 305 | 0.040 |
Why?
|
Glucose | 2 | 2022 | 4340 | 0.040 |
Why?
|
Adolescent | 6 | 2020 | 88902 | 0.040 |
Why?
|
Sodium, Dietary | 1 | 2024 | 426 | 0.040 |
Why?
|
Interferon Regulatory Factors | 1 | 2021 | 272 | 0.040 |
Why?
|
Hemostasis, Surgical | 1 | 2020 | 128 | 0.040 |
Why?
|
Treatment Outcome | 5 | 2018 | 65286 | 0.040 |
Why?
|
Blood Glucose | 2 | 2014 | 6422 | 0.040 |
Why?
|
Life Style | 1 | 2011 | 3926 | 0.040 |
Why?
|
Health Facilities | 1 | 2005 | 578 | 0.040 |
Why?
|
Phenotype | 1 | 2018 | 16722 | 0.040 |
Why?
|
Gene Frequency | 2 | 2017 | 3624 | 0.040 |
Why?
|
Teaching Rounds | 1 | 2024 | 280 | 0.040 |
Why?
|
Vascular Patency | 1 | 2003 | 915 | 0.040 |
Why?
|
Albumins | 1 | 2022 | 578 | 0.040 |
Why?
|
Cell Count | 1 | 2024 | 1826 | 0.040 |
Why?
|
Glucagon-Like Peptide 1 | 1 | 2022 | 374 | 0.040 |
Why?
|
Risk | 1 | 2011 | 9602 | 0.040 |
Why?
|
Protective Agents | 1 | 2020 | 150 | 0.040 |
Why?
|
Vitamin K | 1 | 2022 | 314 | 0.040 |
Why?
|
Patient Discharge | 1 | 2012 | 3466 | 0.040 |
Why?
|
Heart Diseases | 1 | 2012 | 2817 | 0.040 |
Why?
|
Hematuria | 1 | 2020 | 232 | 0.040 |
Why?
|
Nutrition Surveys | 2 | 2018 | 1737 | 0.040 |
Why?
|
Medicare | 2 | 2021 | 6813 | 0.040 |
Why?
|
Blood Proteins | 1 | 2024 | 1194 | 0.040 |
Why?
|
Glomerular Mesangium | 1 | 1999 | 98 | 0.040 |
Why?
|
Mendelian Randomization Analysis | 1 | 2024 | 1044 | 0.040 |
Why?
|
Linear Models | 3 | 2014 | 5873 | 0.040 |
Why?
|
Endothelium, Vascular | 1 | 2010 | 4424 | 0.040 |
Why?
|
Retrospective Studies | 4 | 2023 | 81657 | 0.040 |
Why?
|
Parathyroid Hormone | 2 | 2017 | 1791 | 0.040 |
Why?
|
Medicaid | 1 | 2012 | 2836 | 0.040 |
Why?
|
Polymorphism, Genetic | 1 | 2008 | 4249 | 0.040 |
Why?
|
Hospital Mortality | 1 | 2012 | 5344 | 0.040 |
Why?
|
Sulfones | 1 | 2001 | 447 | 0.040 |
Why?
|
Models, Biological | 1 | 2014 | 9464 | 0.040 |
Why?
|
Public Health | 2 | 2021 | 2680 | 0.040 |
Why?
|
Education | 1 | 2020 | 531 | 0.040 |
Why?
|
Purines | 1 | 2001 | 615 | 0.040 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2024 | 1514 | 0.030 |
Why?
|
Chi-Square Distribution | 2 | 2015 | 3431 | 0.030 |
Why?
|
CpG Islands | 1 | 2021 | 1208 | 0.030 |
Why?
|
Anemia | 1 | 2006 | 1514 | 0.030 |
Why?
|
Mood Disorders | 1 | 2003 | 1127 | 0.030 |
Why?
|
Cathepsin C | 1 | 2015 | 4 | 0.030 |
Why?
|
Ultrasonography | 1 | 2009 | 5990 | 0.030 |
Why?
|
Cuba | 1 | 2015 | 48 | 0.030 |
Why?
|
Central America | 1 | 2015 | 69 | 0.030 |
Why?
|
Interpersonal Relations | 1 | 2003 | 1432 | 0.030 |
Why?
|
Dominican Republic | 1 | 2015 | 78 | 0.030 |
Why?
|
Europe | 1 | 2022 | 3430 | 0.030 |
Why?
|
Urinalysis | 1 | 2018 | 369 | 0.030 |
Why?
|
South America | 1 | 2015 | 180 | 0.030 |
Why?
|
Cultural Competency | 1 | 2018 | 303 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2012 | 7430 | 0.030 |
Why?
|
Up-Regulation | 2 | 2016 | 4143 | 0.030 |
Why?
|
Communication Barriers | 1 | 2018 | 418 | 0.030 |
Why?
|
Informed Consent | 1 | 2021 | 1010 | 0.030 |
Why?
|
Sulfotransferases | 1 | 2015 | 150 | 0.030 |
Why?
|
Hypercalcemia | 1 | 2017 | 425 | 0.030 |
Why?
|
Cell Nucleus | 1 | 2023 | 2875 | 0.030 |
Why?
|
Mississippi | 1 | 2014 | 93 | 0.030 |
Why?
|
Puerto Rico | 1 | 2015 | 380 | 0.030 |
Why?
|
Socioeconomic Factors | 2 | 2021 | 7841 | 0.030 |
Why?
|
rab GTP-Binding Proteins | 1 | 2015 | 247 | 0.030 |
Why?
|
Blood Transfusion | 1 | 2020 | 1308 | 0.030 |
Why?
|
Delayed Graft Function | 1 | 2014 | 50 | 0.030 |
Why?
|
Biopsy, Needle | 1 | 1999 | 1615 | 0.030 |
Why?
|
Trust | 1 | 2018 | 532 | 0.030 |
Why?
|
Health Surveys | 1 | 2003 | 4055 | 0.030 |
Why?
|
Indians, North American | 1 | 2017 | 354 | 0.030 |
Why?
|
Mexico | 1 | 2015 | 769 | 0.030 |
Why?
|
Models, Economic | 1 | 2017 | 719 | 0.030 |
Why?
|
Genome, Human | 2 | 2017 | 4443 | 0.030 |
Why?
|
Gene Knockout Techniques | 1 | 2015 | 804 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 36570 | 0.030 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2014 | 299 | 0.030 |
Why?
|
Research | 1 | 2020 | 1977 | 0.020 |
Why?
|
Diuretics | 1 | 2015 | 614 | 0.020 |
Why?
|
Animals | 5 | 2022 | 168939 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2017 | 1251 | 0.020 |
Why?
|
Hospital Bed Capacity | 1 | 2012 | 200 | 0.020 |
Why?
|
Emotions | 1 | 2003 | 2758 | 0.020 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2011 | 193 | 0.020 |
Why?
|
Health Status | 1 | 2024 | 4087 | 0.020 |
Why?
|
Serum Albumin | 1 | 2014 | 676 | 0.020 |
Why?
|
Life Expectancy | 1 | 2017 | 1248 | 0.020 |
Why?
|
Glucuronidase | 1 | 2011 | 205 | 0.020 |
Why?
|
Absorptiometry, Photon | 1 | 2016 | 1707 | 0.020 |
Why?
|
Carotid Artery, Common | 1 | 2010 | 172 | 0.020 |
Why?
|
Imaging, Three-Dimensional | 1 | 2023 | 4047 | 0.020 |
Why?
|
Myocardial Contraction | 1 | 2015 | 1516 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2022 | 3582 | 0.020 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2011 | 590 | 0.020 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 2015 | 1121 | 0.020 |
Why?
|
Electric Impedance | 1 | 2014 | 791 | 0.020 |
Why?
|
Glucocorticoids | 1 | 1999 | 2158 | 0.020 |
Why?
|
Living Donors | 1 | 2014 | 647 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2021 | 3070 | 0.020 |
Why?
|
Language | 1 | 2018 | 1550 | 0.020 |
Why?
|
Societies, Medical | 1 | 2021 | 3957 | 0.020 |
Why?
|
Mental Health | 1 | 2003 | 3269 | 0.020 |
Why?
|
Myocardial Revascularization | 1 | 2012 | 795 | 0.020 |
Why?
|
Hepatitis C | 1 | 1999 | 1595 | 0.020 |
Why?
|
Interleukin-10 | 1 | 2014 | 1182 | 0.020 |
Why?
|
Phosphates | 1 | 2012 | 763 | 0.020 |
Why?
|
Regional Blood Flow | 1 | 2011 | 1478 | 0.020 |
Why?
|
Interleukin-1beta | 1 | 2014 | 1026 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2000 | 8540 | 0.020 |
Why?
|
Histocompatibility | 1 | 2008 | 327 | 0.020 |
Why?
|
Rats | 2 | 2015 | 23717 | 0.020 |
Why?
|
Receptor, Angiotensin, Type 1 | 1 | 2007 | 153 | 0.020 |
Why?
|
Pilot Projects | 1 | 2020 | 8728 | 0.020 |
Why?
|
Pennsylvania | 1 | 2007 | 615 | 0.020 |
Why?
|
Receptors, Cell Surface | 1 | 2015 | 2815 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6514 | 0.020 |
Why?
|
Models, Cardiovascular | 1 | 2011 | 978 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 2014 | 1996 | 0.020 |
Why?
|
Tibia | 1 | 2011 | 1071 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2018 | 3266 | 0.020 |
Why?
|
Patient Selection | 1 | 2017 | 4252 | 0.020 |
Why?
|
Signal Transduction | 2 | 2022 | 23618 | 0.010 |
Why?
|
Cognition | 1 | 2022 | 7057 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3803 | 0.010 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2015 | 2143 | 0.010 |
Why?
|
Reproducibility of Results | 2 | 2013 | 20146 | 0.010 |
Why?
|
Poverty | 1 | 2015 | 2714 | 0.010 |
Why?
|
Computer Simulation | 1 | 2017 | 6258 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 1999 | 12985 | 0.010 |
Why?
|
Depression | 1 | 2003 | 8225 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5513 | 0.010 |
Why?
|
Drug Prescriptions | 1 | 2012 | 1663 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2011 | 6214 | 0.010 |
Why?
|
Myocytes, Cardiac | 1 | 2011 | 1672 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2014 | 4349 | 0.010 |
Why?
|
Cadaver | 1 | 2007 | 1362 | 0.010 |
Why?
|
Amino Acid Substitution | 1 | 2007 | 1742 | 0.010 |
Why?
|
Ventricular Function, Left | 1 | 2015 | 3934 | 0.010 |
Why?
|
Transcription Factors | 1 | 2021 | 12159 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2011 | 6507 | 0.010 |
Why?
|
Mice | 2 | 2022 | 81898 | 0.010 |
Why?
|
Epidemiologic Methods | 1 | 2003 | 1326 | 0.010 |
Why?
|
Bone Density | 1 | 2011 | 3491 | 0.010 |
Why?
|
Stroke Volume | 1 | 2012 | 5618 | 0.010 |
Why?
|
Heart Ventricles | 1 | 2010 | 3831 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2013 | 14653 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2016 | 11924 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2005 | 4853 | 0.010 |
Why?
|
Chronic Disease | 1 | 2011 | 9358 | 0.010 |
Why?
|
Registries | 1 | 2012 | 8352 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2011 | 14473 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2013 | 15912 | 0.010 |
Why?
|
DNA | 1 | 2007 | 7210 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2011 | 22351 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2011 | 18329 | 0.010 |
Why?
|
Graft Rejection | 1 | 2005 | 4504 | 0.010 |
Why?
|